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the contrast-enhanced MRI imaging. CTV2 encompassed the 
whole brain. Only the PTV1 dose was escalated (planned dose 
escalation: 35 Gy, 40 Gy, 45 Gy, 50 Gy) while the PTV2 dose 
remained the same (30 Gy/3 Gy/fractions). Dose-limiting 
toxicities (DLTs) were defined as any treatment-related non-
hematological adverse effects rated as grade ≥ 3, or any 
hematological toxicity rated as ≥ 4 by CTCAE scale, v. 4.0. 
MTD was exceeded if > 2 of 6 patients in a cohort 
experienced dose-limiting toxicity (DLT).  
Results: 27 consecutive patients (pts) were treated (PTV1 
dose: 35 Gy, 8 pts; 40 Gy, 6 pts; 45 Gy, 6 pts; 50 Gy, 7 pts). 
The number of treated brain lesions was: 1 (17 pts), 2 (4 pts), 
3 (5 pts) and 4 (1 pt). Three pts experienced a DLT: 1 pt (2nd 
dose level) developed a grade 3 skin toxicity, 1 pt had a 
grade 3 neurological toxicity (4th dose level) and 1 pt had a 
brain hemorrhage (4th dose level). Nineteen pts experienced 
cutaneous (17 pts) and/or neurological (10 pts) grade 1-2 
acute toxicity. The response to treatment was evaluable in 
16 pts: 1 pt (6.2%) disease progression, 2 pts (12.5%) stable 
disease, 10 pts (62.5%) partial response and 3 pts (18.8%) 
complete response. Median and 1-year overall survival were 
13 months and 51.9%, respectively. Late toxicity was not 
recorded. 
Conclusions: This is the first prospective trial demonstrating 
that a radiation dose of 50 Gy in 10 fractions can be 
delivered by using a SIB IMRT technique without unacceptable 
toxicity in patients with < 5 brain metastases. A phase II trial 
(ISIDE-BM-2) is in progress to evaluate the response and the 
time to progression. 
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Purpose/Objective: Stereotactic ablative body radiotherapy 
(SABR) is the standard treatment modality for a limited 
number of brain metastases (BM). Several models for survival 
prediction have been published, such as the commonly used 
Recursive Partitioning Analysis (RPA), Golden Grading System 
(GGS), and the Disease Specific Graded Partitioning Analysis 
(DS-GPA). All published models have limitations for 
prediction of survival after SABR for BM: e.g. small proportion 
of patients in the favorable prognostic group, a low 
sensitivity for the identification of patients with long term 
survival, and some models are complex to use (e.g. DS-GPA). 
In this study, a new prognostic model is developed with the 
aim of overcoming above mentioned limitations. 
Materials and Methods: Based on published models and 
clinical practice a new prognostic model was developed. Its 
clinical utility was tested for prediction of early death (<3 
months) and long term survival (>12 months) in 297 patients 
with 1 up to 4 newly diagnosed BM treated with Linac-based 
SABR at our department between July 2004 and July 2014. 
Prescribed dose at the edge of the PTV was in the range of 15 
up to 24Gy in 1 or 3 fractions.  
Results: In the published models the two most important 
prognostic factors were: WHO performance status and 
presence of extracranial metastases. Poor performance 
status only was identified as the poor prognostic group 
according to Dutch guidelines. Remaining patient cohort was 
divided based on the presence of extracranial metastases. 
The developed model is a simplified version of the commonly 
used RPA, and was named Simplified Recursive Partitioning 
Analysis (SRPA). 
- SRPA class I: WHO performance status 0/1 & no extracranial 
metastases 
- SRPA class II: WHO performance status 0/1 & extracranial 
metastases 
- SRPA class III: WHO performance status of 2 or more 
Median age was 63 years and the majority of patients had 
non-small cell lung cancer (64%). The median survival after 
SABR was 9 months, with 3 months-, 1 year-, and 5 years 
survival of respectively 81%, 36%, and 9%. The patient 
distribution was most balanced in the SRPA with 48% of 
patients in the favorable prognostic class (vs 20%-29% in the 
other models, Table 1). Sensitivity for prediction of long-
term survival was highest using the SRPA (56% vs 16-46% in 
other classes). The specificity of predicting 3-months death 
in the poor prognostic class was high in all scores (range 86% 
up to 98%). The SRPA was valid in an external SABR for 1-3 BM 
patients data set. 
 
 
 
 
Conclusions: The SRPA had the highest clinical utility for 
survival prediction after SABR for BM compared to the RPA, 
DS-GPA, and GGS. The SRPA is very simple in use, assembles 
to clinical practice, has a balanced patient distribution 
between the favorable and intermediate group, the highest 
sensitivity for prediction of long term survival, was specific 
for prediction of early death, and was validated in an 
external population. Further research will focus on further 
validation in other BM populations and exploration of the 
predictive value of advanced techniques such as radiomics, 
biomarkers, and statistical modeling. 
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